A randomized phase 2 study of combination cediranib and olaparib versus olaparib alone as recurrence therapy in platinum-sensitive ovarian cancer

BACKGROUND: Olaparib is an oral poly(ADP-ribose) polymerase inhibitor and cediranib is an oral anti-angiogenic with activity against VEGFR-1, 2, and 3. Both agents have antitumor activity in women with recurrent ovarian cancer, and the combination of these agents was active and had manageable toxici...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Lancet Oncol
Egile Nagusiak: Liu, Joyce F., Barry, William T., Birrer, Michael, Lee, Jung-Min, Buckanovich, Ronald J., Fleming, Gini F., Rimel, BJ, Buss, Mary K., Nattam, Sreenivasa, Hurteau, Jean, Luo, Weixiu, Quy, Philippa, Whalen, Christin, Obermayer, Lisa, Lee, Hang, Winer, Eric P., Kohn, Elise C., Ivy, S. Percy, Matulonis, Ursula A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4294183/
https://ncbi.nlm.nih.gov/pubmed/25218906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(14)70391-2
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak